InSilico Medicine Cayman (HKG: 03696)

Biotech · Hong Kong, MA · Founded 2014 · Publicly Held

InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. InSilico Medicine Cayman (HKG: 03696) is based in Hong Kong, MA and was founded in 2014. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.7 billion (Dec 2025). It has raised $842 million across 6 recorded rounds; the latest was a $13 million Series E extension (final close) in Jun 2025.

Last price · $/share
—
Implied valuation
$1.7B
Total raised
$841.9M
Last round
Series E extension (final close)
Jun 2025
What is InSilico Medicine Cayman (HKG: 03696) worth?
$1.7Blast known valuation

InSilico Medicine Cayman (HKG: 03696) last raised $13.0M in its Series E extension (final close) (Jun 2025).

Free account
More of InSilico Medicine Cayman (HKG: 03696) with a free account
  • ·The complete investor list: 50 names
  • ·Watch InSilico Medicine Cayman (HKG: 03696): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

InSilico Medicine Cayman (HKG: 03696) funding history

6 rounds
DateRoundRaisedPost-money
Jun 2025Series E extension (final close)$13.0M▮
Mar 2025Series E$110.0M▮
Aug 2022Series D2$35.0M▮
Jun 2022Series D$60.0M▮
Jun 2021Series C$255.0M▮
Sep 2019Series B$37.0M▮
Unlock post-money valuations

Membership and data by Private Market View

InSilico Medicine Cayman (HKG: 03696) valuation

InSilico Medicine Cayman (HKG: 03696) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.7 billion (Dec 2025). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.

How much has InSilico Medicine Cayman (HKG: 03696) raised?

InSilico Medicine Cayman (HKG: 03696) has raised $842 million across 6 recorded rounds since 2019. The largest was a $60 million Series D in Jun 2022; the most recent was a $13 million Series E extension (final close) in Jun 2025.

Comparable companies

Comparable biotech names by valuation on PrivateMarketView: Xaira Therapeutics ($3.5 billion), Chai Discovery ($1.3 billion) and Merida Biosciences ($228 million).

How InSilico Medicine Cayman (HKG: 03696)'s valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For InSilico Medicine Cayman (HKG: 03696), too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about InSilico Medicine Cayman (HKG: 03696)

What is InSilico Medicine Cayman (HKG: 03696) worth?
InSilico Medicine Cayman (HKG: 03696)'s last known valuation is $1.7B.
How much has InSilico Medicine Cayman (HKG: 03696) raised?
InSilico Medicine Cayman (HKG: 03696) has raised $841.9M in total funding across 6 recorded rounds.
When did InSilico Medicine Cayman (HKG: 03696) last raise?
InSilico Medicine Cayman (HKG: 03696) last raised in Jun 2025 (Series E extension (final close)), raising $13.0M.